He Started a Psychedelics Company. It Sold for $700M.

Resumen

This video explores the journey of starting a for-profit psychedelics company focused on therapeutic innovation. The speaker explains how reading Michael Pollan's book shifted his perspective, leading him to invest in the Yale Center for Psychedelic Research. He details why he chose methylone as a therapeutic alternative to MDMA, citing its better safety profile, shorter duration, and compatibility with standard healthcare. Finally, he shares the business philosophy of being the second mouse in a market, learning from the early mistakes of competitors to build a scalable and effective medical solution for conditions like PTSD.

Temas tratados

• Initial inspiration from literature
• Investment in psychedelic research

+6 temas más (contenido completo al seguir el canal)

Extracto de la transcripción

How to change your mind by Michael Pollen. What did that do for you? >> So I reached the age of 54 which was eight years ago and had never thought about psychedelics at all. Certainly never tried anything. Just never and didn't know very much. Read the Michael Pollen book. It was on the New York Times in 2017 10 best books of the year which is something I always go over to see what I should be reading there. Read the book and it literally did change my mind. It was called how to change your mind. And I realized later than most people that I was wrong, that these medicines could be very useful for people and that there was a lot of academic results even at the time that showed that they could help PTSD and depression and anxiety. And at the time I was still on the board of Yale. So I went and I realized at Yale and I think you talked to John Crystal at one point. >> Interviewed John Cryst…